Meanwhile, Moderna has progressed nicely on its cost cutting program, and beyond this year, plans to reduce as much as $1.7 ...

A study in Nature Aging from researchers at the UC Davis School of Medicine has identified specific microRNAs—non-coding RNAs ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...

Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved ...

GERMAN drug developer BioNTech has signed an agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) to manufacture ...